Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multiple-dose Clinical Study to Evaluating the Safety, Tolerability and Preliminary Efficacy of a Single Intracerebroventricular Injection of HG204 for the Treatment of MECP2 Duplication Syndrome

NCT06615206 is registered in ClinicalTrials.gov with HuidaGene Therapeutics Co., Ltd. as lead sponsor.

NCT NCT06615206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06615206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multiple-dose Clinical Study to Evaluating the Safety, Tolerability and Preliminary Efficacy of a Single Intracerebroventricular Injection of HG204 for the Treatment of MECP2 Duplication Syndrome
Lead sponsor
HuidaGene Therapeutics Co., Ltd.
Phase
Not applicable
Overall status
Recruiting
Start date
October 30, 2024
Completion date
October 31, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mecp2 duplication syndrome